AbTherx licenses Atlas antibody discovery platform to Athenova for targeted alpha cancer therapies

Athenova will use AbTherx's fully human antibody discovery technology for astatine-211 radiopharmaceutical programmes under a licensing agreement involving research payments, milestones and royalties.
On 18 November 2026, AbTherx announced a licensing agreement with Athenova Therapeutics giving the French biotechnology company access to its Atlas Full Human Diversity Mice platform to discover fully human antibodies for targeted alpha radiopharmaceutical development.
Athenova receives development and commercialisation rights to antibodies discovered under the licence in exchange for research payments, development milestones and royalties, with financial amounts undisclosed and therapeutic candidates still under development.
Field | Content |
Alert Type | Deal |
Companies | AbTherx; Athenova Therapeutics |
Deal Type | Antibody discovery platform licensing agreement |
Asset or Company | Atlas Full Human Diversity Mice platform; antibodies discovered for Athenova's targeted alpha radiopharmaceutical programmes |
Therapy Area(s) | Oncology; targeted alpha radiopharmaceutical therapy |
Technology or Modality | Fully human antibody discovery using transgenic Atlas mice; investigational astatine-211 targeted alpha radiopharmaceutical conjugates |
Deal Value | Financial amounts not disclosed; consideration comprises research payments, development milestones and royalties on net sales. |
Geography | United States and France; platform access supported through a European research partner |
What Happened | AbTherx licensed access to its Atlas Full Human Diversity Mice technology to Athenova Therapeutics for the discovery of fully human antibodies intended for the company's astatine-211 radiopharmaceutical conjugate programmes. |
Why It Matters | Targeted alpha radiopharmaceutical development requires suitable targeting molecules. The agreement gives Athenova access to an antibody discovery platform while retaining development and commercialisation rights to antibodies generated under the licence. |
Supporting Context | Athenova is a France-based biotechnology company developing targeted alpha therapies using astatine-211. AbTherx provides transgenic mouse technology designed to generate diverse fully human therapeutic antibody candidates. |
Strategic Rationale | Athenova gains access to specialised antibody discovery capabilities without developing its own transgenic mouse platform, while AbTherx expands its Atlas licensing activities into targeted radiopharmaceutical discovery. |
Potential Impact | The collaboration could generate antibody candidates suitable for further development as targeted alpha radiopharmaceuticals, although successful candidate selection, clinical safety and therapeutic efficacy remain to be demonstrated. |
Key Takeaway | AbTherx has licensed its Atlas platform to Athenova for investigational astatine-211 cancer therapy discovery under undisclosed financial terms involving research payments, milestones and royalties. |
What to Watch | Identification of antibody leads, progress towards radiopharmaceutical development candidates, preclinical evaluation and subsequent clinical development plans. |
Primary Source | https://www.abtherx.com/abtherx-licenses-atlas-platform-to-athenova-therapeutics-for-next-generation-targeted-alpha-radiopharmaceutical-discovery/ |
Relevant Date | 18 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments